IGF1R inhibitors have shown efficacy in numerous pre-clinical studies in solid tumors including non-small cell lung cancer, breast cancer, adrenocortical carcinoma, and Ewing sarcoma[16], and also in hematologic malignancies such as myeloma, CLL, B-ALL, T-ALL, and AML[4, 17–20]. Here, IGF1R is linked to acute lymphoblastic leukemia.